2 recruiting, 1 completed, 1 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 2, Completed 1, Terminated 1 |
Follow Non-cystic Fibrosis Bronchiectasis: new trials by email Literature Review of Non-cystic Fibrosis Bronchiectasis trials Research Report on Non-cystic Fibrosis Bronchiectasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis HSK31858, tablet - Non-cystic Fibrosis Bronchiectasis | Phase 3 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 669 | 2025-09-28 | 2026-06-01 |
| A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis HSK31858, tablet, Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 3 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 669 | 2024-09-30 | 2024-10-28 |
| Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis Benralizumab, Placebo to Benralizumab - Non-cystic Fibrosis Bronchiectasis | Phase 3 | Terminated | AstraZeneca | 100 | 2021-07-21 | 2025-07-20 |
| A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis Brensocatib 10 mg, Brensocatib 25 mg, Placebo - Non-Cystic Fibrosis Bronchiectasis | Phase 3 | Completed | Insmed Incorporated | 1767 | 2020-12-01 | 2025-12-16 |
Tablets (2) · benralizumab (1) · brensocatib (1)
Haisco Pharmaceutical Group Co., Ltd. (2) · AstraZeneca (1) · Insmed Incorporated (1)
China (3) · Argentina (2) · Australia (2) · Canada (2) · Denmark (2) · Germany (2) · Italy (2) · Poland (2) · South Korea (2) · Spain (2) · United Kingdom (2) · United States (2) · Austria (1) · Belgium (1) · Brazil (1)
PMID 35976570, PMID 39040578, PMID 40267423, PMID 41519018, PMID 42461571